Brokerages Anticipate Strongbridge Biopharma plc (NASDAQ:SBBP) Will Post Quarterly Sales of $5.24 Million

Equities research analysts expect Strongbridge Biopharma plc (NASDAQ:SBBP) to announce $5.24 million in sales for the current quarter, Zacks reports. Four analysts have made estimates for Strongbridge Biopharma’s earnings, with estimates ranging from $5.06 million to $5.56 million. Strongbridge Biopharma reported sales of $5.35 million during the same quarter last year, which would suggest a negative year over year growth rate of 2.1%. The company is expected to issue its next earnings report on Wednesday, October 30th.

According to Zacks, analysts expect that Strongbridge Biopharma will report full-year sales of $0.00 for the current financial year. For the next year, analysts expect that the company will post sales of $31.23 million, with estimates ranging from $23.17 million to $48.34 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Strongbridge Biopharma.

Strongbridge Biopharma (NASDAQ:SBBP) last issued its earnings results on Wednesday, July 31st. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.01. The company had revenue of $6.08 million for the quarter, compared to the consensus estimate of $4.82 million. Strongbridge Biopharma had a return on equity of 54.23% and a net margin of 181.52%.

A number of research firms have issued reports on SBBP. ValuEngine downgraded Strongbridge Biopharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday, May 1st. TheStreet downgraded Strongbridge Biopharma from a “c-” rating to a “d+” rating in a research note on Wednesday, May 15th. HC Wainwright reaffirmed a “buy” rating on shares of Strongbridge Biopharma in a research note on Thursday. Zacks Investment Research downgraded Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research note on Friday. Finally, BidaskClub raised Strongbridge Biopharma from a “strong sell” rating to a “sell” rating in a research note on Friday, April 26th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $13.07.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SBBP. Stonebridge Capital Management Inc. purchased a new position in Strongbridge Biopharma during the 1st quarter valued at $55,000. Stifel Financial Corp purchased a new position in Strongbridge Biopharma during the 4th quarter valued at $73,000. Oppenheimer & Co. Inc. boosted its holdings in Strongbridge Biopharma by 90.8% during the 1st quarter. Oppenheimer & Co. Inc. now owns 45,448 shares of the biotechnology company’s stock valued at $226,000 after acquiring an additional 21,626 shares during the period. Private Advisors LLC purchased a new position in Strongbridge Biopharma during the 1st quarter valued at $263,000. Finally, Tibra Equities Europe Ltd purchased a new position in Strongbridge Biopharma during the 1st quarter valued at $324,000. 50.12% of the stock is currently owned by hedge funds and other institutional investors.

SBBP traded down $0.07 on Monday, hitting $2.51. 76,584 shares of the company’s stock traded hands, compared to its average volume of 110,381. The firm has a 50 day simple moving average of $3.00. The company has a market capitalization of $140.85 million, a price-to-earnings ratio of 8.10 and a beta of 0.84. Strongbridge Biopharma has a one year low of $2.50 and a one year high of $6.55.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.

Read More: Cost of Capital

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.